1) Have received the third doses of Vaccine against COVID-19 in the past at the time of informed consent, 2)Pregnant or possibly pregnant women, women desiring to become pregnant before completing follow-up examination and breastfeeding women,3) Patients with progressive ossifying fibrodysplasia,4) Patients having an underlying disease, such as serious cardiovascular diseases, serious renal diseases, serious hepatic diseases, serious hematological diseases, serious developmental disorders, serious respiratory diseases, serious diabetes mellitus, etc.,5) Subjects with a history of convulsions,6) Subjects having been diagnosed with immunodeficiency or having a close relative with congenital immunodeficiency,7) Subjects possibly being allergic to any ingredient of the study product, 8) Subjects who participated in another clinical trial and have received another investigational product (excluding placebo) within 4 months (120 days) prior to the date of the first dose of study product in this study, or those who plan to participate in another clinical trial during their participation in this study,9) Subjects who have received transfusion or a gamma globulin preparation within 3 months (90 days), or a bolus therapy (>=200 mg/kg) with a gamma globulin preparation within 6 months (180 days), prior to the date of the first dose of study product,10) Subject who have received any treatments that may affect the immune function within 6 months (180 days) prior to the date of the first dose of study product, including radiotherapy, immunosuppressants (except for external use), immunosuppressive therapy, antirheumatics, adrenocorticotropic hormones, or corticosteroids (treatment at prednisolone equivalent doses >=2 mg/kg/day for >=14 days, except for external use.),11) Subjects who have received live vaccine within 1 month prior to enrollment or inactivated vaccine within 1 week prior to enrollment12) Subjects who have a history of breakthrough infection if they wish to be vaccinated with study product13) Subjects who are judged by the principal investigator or the sub investigator as ineligible for the study as a result of the screening test, or Subject being otherwise ineligible for this study in the principal investigator's or sub investigator's opinion.

1) Have received the third doses of Vaccine against COVID-19 in the past at the time of informed consent, 2)Pregnant or possibly pregnant women, women desiring to become pregnant before completing follow-up examination and breastfeeding women,3) Patients with progressive ossifying fibrodysplasia,4) Patients having an underlying disease, such as serious cardiovascular diseases, serious renal diseases, serious hepatic diseases, serious hematological diseases, serious developmental disorders, serious respiratory diseases, serious diabetes mellitus, etc.,5) Subjects with a history of convulsions,6) Subjects having been diagnosed with immunodeficiency or having a close relative with congenital immunodeficiency,7) Subjects possibly being allergic to any ingredient of the study product, 8) Subjects who participated in another clinical trial and have received another investigational product (excluding placebo) within 4 months (120 days) prior to the date of the first dose of study product in this study, or those who plan to participate in another clinical trial during their participation in this study,9) Subjects who have received transfusion or a gamma globulin preparation within 3 months (90 days), or a bolus therapy (>=200 mg/kg) with a gamma globulin preparation within 6 months (180 days), prior to the date of the first dose of study product,10) Subject who have received any treatments that may affect the immune function within 6 months (180 days) prior to the date of the first dose of study product, including radiotherapy, immunosuppressants (except for external use), immunosuppressive therapy, antirheumatics, adrenocorticotropic hormones, or corticosteroids (treatment at prednisolone equivalent doses >=2 mg/kg/day for >=14 days, except for external use.),11) Subjects who have received live vaccine within 1 month prior to enrollment or inactivated vaccine within 1 week prior to enrollment12) Subjects who have a history of breakthrough infection if they wish to be vaccinated with study product13) Subjects who are judged by the principal investigator or the sub investigator as ineligible for the study as a result of the screening test, or Subject being otherwise ineligible for this study in the principal investigator's or sub investigator's opinion.